Case number 1:20-cv-00985
ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 7, 2024 | 286 | Report to the Commissioner of Patents and Trademarks. (ntl) (Entered: 05/07/2024) (6) |
| Jan 29, 2024 | 285 | NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 283 Notice of Appeal (Federal Circuit) filed by MSN Pharmaceuticals, Inc. USCA Case Number 2024-1401. (ntl) (Entered: 01/29/2024) (4) |
| Jan 24, 2024 | 284 | Official Transcript of Motion Transcript held on 09.27.2023 before Judge Gregory B. Williams. Court Reporter/Transcriber Michele Rolfe,Email: michele_rolfe@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/14/2024. Redacted Transcript Deadline set for 2/26/2024. Release of Transcript Restriction set for 4/23/2024. (Rolfe, Michele) (Entered: 01/24/2024) (87) |
| Jan 18, 2024 | 283 | Notice of Appeal* (1) |
| Jan 11, 2024 | 282 | FINAL ORDER: Final Judgment is entered in favor of Plaintiff Acadia and against Defendants MSN -- Party MSN Pharmaceuticals, Inc. and MSN Laboratories Private Limited terminated. Attorney James S. Green, Jr terminated. Signed by Judge Gregory B. Williams on 1/11/24. (ntl) (Entered: 01/11/2024) (2) |
| Jan 10, 2024 | 281 | Letter to The Honorable Gregory B. Williams from James S. Green, Jr. regarding the December 13, 2023 Memorandum Order - re 275 Memorandum and Order,. (Attachments: # 1 Exhibit A - Proposed Form of Order)(Green, James) (Entered: 01/10/2024) (0) |
| Jan 8, 2024 | 278 | MOTION for Pro Hac Vice Appearance of Attorney Peter E. Conway - filed by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 01/08/2024) (3) |
| Jan 8, 2024 | 279 | Pro Hac Vice Fee - Credit Card Payment received for Peter Conway. ( Payment of $ 50, receipt number ADEDC-4308862).(Streifthau-Livizos, Michelle) (Entered: 01/08/2024) (0) |
| Jan 8, 2024 | 280 | NOTICE requesting Clerk to remove Rebecca A. Hilgar as co-counsel. Reason for request: no longer with the firm. (Streifthau-Livizos, Michelle) (Entered: 01/08/2024) (1) |
| Dec 29, 2023 | 277 | NOTICE of Withdrawal of Appearance of Shashank Upadhye, Yixin Tang, and Brent Batzer as counsel for Defendants MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc. (Green, James) (Entered: 12/29/2023) (2) |
| Dec 13, 2023 | 275 | MEMORANDUM ORDER: IT IS HEREBY ORDERED that: 1. MSN's Motion for Summary Judgment of Invalidity of U.S. Patent No. 7,601,740 For Double Patenting (D.I. 260) is DENIED. 2. Acadia's Cross Motion for Summary Judgment and No Invalidity of Claim 26 of U.S. Patent No. 7,601,740 (D.I. 262) is GRANTED. Signed by Judge Gregory B. Williams on 12/13/23. (ntl) Modified on 12/19/2023 (ntl). (Main Document 275 replaced on 12/19/2023) (ntl). Modified on 12/19/2023 (ntl). (Entered: 12/13/2023) (16) |
| Dec 13, 2023 | 276 | ORAL ORDER: IT IS HEREBY ORDERED that MSN's Motion for Leave to File Response to Plaintiff's Notice of Subsequent Authority (D.I. 273) is DENIED-AS-MOOT. ORDERED by Judge Gregory B. Williams on 12/13/23. (ntl) (Entered: 12/13/2023) (0) |
| Nov 20, 2023 | 274 | Letter to The Honorable Gregory B. Williams from Michelle C. Streifthau-Livizos regarding Timing of Decision. (Attachments: # 1 Exhibit A)(Streifthau-Livizos, Michelle) (Entered: 11/20/2023) (0) |
| Oct 4, 2023 | 273 | MOTION for Leave to File Response to Plaintiff's Notice of Subsequent Authority - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Green, James) (Entered: 10/04/2023) (0) |
| Sep 29, 2023 | 272 | NOTICE of Plaintiff's Notice of Subsequent Authority by ACADIA Pharmaceuticals Inc. (Attachments: # 1 Exhibit A)(Streifthau-Livizos, Michelle) (Entered: 09/29/2023) (0) |
| Sep 8, 2023 | 270 | RESPONSE to Motion re 269 MOTION for Leave to File Response to Defendants' Citation of Subsequent Authority filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Green, James) (Entered: 09/08/2023) (3) |
| Sep 8, 2023 | 271 | ORDER re 269 MOTION for Leave to File Response to Defendants' Citation of Subsequent Authority filed by ACADIA Pharmaceuticals Inc. Signed by Judge Gregory B. Williams on 9/8/23. (ntl) (Entered: 09/08/2023) (1) |
| Sep 7, 2023 | 269 | MOTION for Leave to File Response to Defendants' Citation of Subsequent Authority - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Text of Proposed Order)(Streifthau-Livizos, Michelle) (Entered: 09/07/2023) (0) |
| Sep 5, 2023 | 268 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding New authority relating to summary judgment briefing - re 260 MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting, 267 Oral Order,,,, Set Hearings,,, 259 Opening Brief in Support, 10 Answer to Complaint,, Counterclaim, 8 Affidavit of Service, SO ORDERED,, Set/Reset Answer Deadline(s), 9 STIPULATION TO EXTEND TIME for Defendants Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. to answer, move or otherwise respond to the Complaint to September 1, 2020, 266 Notice (Other), 263 Reply Brief,, 261 Answering Brief in Opposition,. (Attachments: # 1 Exhibit New Authority)(Green, James) (Entered: 09/05/2023) (0) |
| Jun 30, 2023 | 267 | ORAL ORDER: Having reviewed the parties' Notice of Completion of Briefing and Joint Request for Oral Argument (D.I. 266), IT IS HEREBY ORDERED that a hearing on MSN Laboratories Pvt. Ltd.'s and MSN Pharmaceuticals, Inc.'s (collectively, "MSN") Motion for Summary Judgment (D.I. 260) and ACADIA Pharmaceuticals Inc.'s ("ACADIA") Cross-Motion for Summary Judgment (D.I. 262) is scheduled for September 27, 2023 at 1:00 p.m. The Court will allocate two (2) hours for the hearing with the time to be split equally between the parties. Any slide presentations the parties wish to use during the hearing shall be emailed (in PDF format) to gbw_civil@ded.uscourts.gov no later than 48 hours prior to the hearing with hard copies delivered to the Clerk's office within one hour thereafter. Ordered by Judge Gregory B. Williams on 6/30/2023. (etg) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 266 | Joint NOTICE of Completion of Briefing and Request for Oral Argument by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc. re 256 SO ORDERED, Terminate Deadlines, Terminate Deadlines and Hearings (Green, James) (Entered: 06/29/2023) (2) |
| Jun 28, 2023 | 265 | SUR-REPLY BRIEF re 260 MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting filed by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 06/28/2023) (15) |
| Jun 21, 2023 | 263 | REPLY BRIEF re 262 Cross MOTION for Summary Judgment and no invalidity of claim 26 of U.S. Patent No. 7,601,740, 260 MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting MSNS REPLY BRIEF IN SUPPORT OF ITS MOTION FOR SUMMARY JUDGMENT, AND MSNS ANSWERING BRIEF IN OPPOSITION TO ACADIAS CROSS-MOTION FOR SUMMARY JUDGMENT, REGARDING INVALIDITY OF U.S. PATENT NO. 7,601,740 FOR OBVIOUSNESS-TYPE DOUBLE PATENTING filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Green, James) (Entered: 06/21/2023) (14) |
| Jun 21, 2023 | 264 | DECLARATION re 263 Reply Brief,, DECLARATION OF BRENT BATZER, ESQ. IN SUPPORT OF REPLY by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit)(Green, James) (Entered: 06/21/2023) (Main Document) (1) |
| Jun 21, 2023 | 264 | DECLARATION re 263 Reply Brief,, DECLARATION OF BRENT BATZER, ESQ. IN SUPPORT OF REPLY by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit)(Green, James) (Entered: 06/21/2023) (Exhibit) (17) |
| Jun 14, 2023 | 261 | ANSWERING BRIEF in Opposition re 260 MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting filed by ACADIA Pharmaceuticals Inc..Reply Brief due date per Local Rules is 6/21/2023. (Attachments: # 1 Exhibit A)(Streifthau-Livizos, Michelle) (Entered: 06/14/2023) (Main Document) (25) |
| Jun 14, 2023 | 262 | Cross MOTION for Summary Judgment and no invalidity of claim 26 of U.S. Patent No. 7,601,740 - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Text of Proposed Order)(Streifthau-Livizos, Michelle) (Attachment 1 replaced on 6/22/2023) (mpb). (Entered: 06/14/2023) (Main Document) (2) |
| Jun 14, 2023 | 262 | Cross MOTION for Summary Judgment and no invalidity of claim 26 of U.S. Patent No. 7,601,740 - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Text of Proposed Order)(Streifthau-Livizos, Michelle) (Attachment 1 replaced on 6/22/2023) (mpb). (Entered: 06/14/2023) (Text of Proposed Order) (1) |
| Jun 14, 2023 | 261 | ANSWERING BRIEF in Opposition re 260 MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting filed by ACADIA Pharmaceuticals Inc..Reply Brief due date per Local Rules is 6/21/2023. (Attachments: # 1 Exhibit A)(Streifthau-Livizos, Michelle) (Entered: 06/14/2023) (Exhibit A) (2) |
| May 15, 2023 | 260 | MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Green, James) (Entered: 05/15/2023) (Main Document) (2) |
| May 15, 2023 | 260 | MOTION for Summary Judgment of Invalidity of U.S. Patent NO. 7,601,740 For Double Patenting - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(Green, James) (Entered: 05/15/2023) (Text of Proposed Order) (1) |
| May 12, 2023 | 259 | OPENING BRIEF in Support of Its Motion for Summary Judgment of Invalidity of U.S. Patent No. 7601,740 for Double Patenting filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 5/26/2023. (Attachments: # 1 Exhibit - Declaration of Brent Batzer, Esq., # 2 Exhibit 1-4 to Batzer Declaration)(Green, James) (Entered: 05/12/2023) (Main Document) (25) |
| May 12, 2023 | 259 | OPENING BRIEF in Support of Its Motion for Summary Judgment of Invalidity of U.S. Patent No. 7601,740 for Double Patenting filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 5/26/2023. (Attachments: # 1 Exhibit - Declaration of Brent Batzer, Esq., # 2 Exhibit 1-4 to Batzer Declaration)(Green, James) (Entered: 05/12/2023) (Exhibit - Declaration of Brent Batzer, Esq.) (2) |
| May 12, 2023 | 259 | OPENING BRIEF in Support of Its Motion for Summary Judgment of Invalidity of U.S. Patent No. 7601,740 for Double Patenting filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 5/26/2023. (Attachments: # 1 Exhibit - Declaration of Brent Batzer, Esq., # 2 Exhibit 1-4 to Batzer Declaration)(Green, James) (Entered: 05/12/2023) (Exhibit 1-4 to Batzer Declaration) (30) |
| Apr 28, 2023 | 257 | Joint STIPULATION Stipulation of Infringement and Narrowing Issues by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (4) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Main Document) (12) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 1) (4) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 2) (30) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 3) (27) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 4) (30) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 5) (9) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 6) (2) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 7) (30) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 8) (3) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 9) (4) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 10) (3) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 11) (15) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 12) (15) |
| Apr 28, 2023 | 258 | Joint STATEMENT of Undisputed Facts by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13)(Streifthau-Livizos, Michelle) (Entered: 04/28/2023) (Exhibit 13) (13) |
| Apr 11, 2023 | 256 | SO ORDERED, re [255-1] Stipulation and Order regarding briefing schedule for summary judgment. The pretrial conference and bench trial are adjourned. Signed by Judge Gregory B. Williams on 4/10/23. (ntl) (Entered: 04/11/2023) (3) |
| Apr 6, 2023 | 255 | Joint STATUS REPORT by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Stipulation and [Proposed] Order)(Streifthau-Livizos, Michelle) (Entered: 04/06/2023) (Main Document) (3) |
| Apr 6, 2023 | 255 | Joint STATUS REPORT by ACADIA Pharmaceuticals Inc.. (Attachments: # 1 Stipulation and [Proposed] Order)(Streifthau-Livizos, Michelle) (Entered: 04/06/2023) (Stipulation and [Proposed] Order) (3) |
| Apr 4, 2023 | 254 | STIPULATION of Dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a) as to Zydus by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 04/04/2023) (2) |
| Mar 29, 2023 | 253 | STIPULATION of Dismissal as to Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. and the '740 and '285 patents by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 03/29/2023) (3) |
| Jan 20, 2023 | 252 | STIPULATION TO EXTEND TIME Expert Discovery Deadlines and Removal of Daubert Motino Deadlines to 2/17/2023 - filed by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 01/20/2023) (3) |
| Dec 20, 2022 | 251 | ORAL ORDER: Having reviewed the parties' letters (D.I. 238, D.I. 246, D.I. 247), IT IS HEREBY ORDERED that Defendants MSN Laboratories Pvt. Ltd.'s and MSN Pharmaceuticals, Inc.'s ("MSN") request for leave to file a summary judgment motion of invalidity of U.S. patent 7,601,740 (the "'740 patent") based on an obviousness-type double patenting ("OTDP") argument (D.I. 238) is DENIED. It is the general practice of this Court to not hear case dispositive motions in ANDA cases and the Court is not persuaded there is a clear and compelling reason to deviate from that general practice in this case. See Judge William's Form Scheduling Order for ANDA Cases para. 12 ("[a]bsent agreement between the parties, and prior approval from the Court, the Court will not hear case dispositive motions in ANDA cases"); see also Judge Noreika's Form Scheduling Order for ANDA Cases para. 14 (same). ORDERED by Judge Gregory B. Williams on 12/20/22. (ntl) (Entered: 12/20/2022) (0) |
| Dec 16, 2022 | 250 | NOTICE OF SERVICE of Sur Reply report of Stuart H. Isaacson, M.D., F.A.A.N. filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 12/16/2022) (2) |
| Dec 14, 2022 | 248 | NOTICE OF SERVICE of Sur-Reply report of Dennis M. Fischer, M.D. filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 12/14/2022) (2) |
| Dec 14, 2022 | 249 | NOTICE OF SERVICE of Sur Reply report of Professor Bryan L. Roth, M.D., Ph.D.; Sur Reply report of Dr. William L. Jorgensen and Reply report of Sean D. Sheridan, Ph.D. filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 12/14/2022) (2) |
| Dec 5, 2022 | 247 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment - re 1 Complaint, 246 Letter. (Attachments: # 1 Exhibit A)(Green, James) (Entered: 12/05/2022) (Main Document) (2) |
| Dec 5, 2022 | 247 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment - re 1 Complaint, 246 Letter. (Attachments: # 1 Exhibit A)(Green, James) (Entered: 12/05/2022) (Exhibit A) (3) |
| Dec 2, 2022 | 245 | NOTICE requesting Clerk to remove Aubrey J. Morin as co-counsel. Reason for request: No longer with the firm of Saul Ewing LLP. (Morin, Aubrey) (Entered: 12/02/2022) (1) |
| Dec 2, 2022 | 246 | Letter to The Honorable Gregory B. Williams from Michelle C. Streifthau-Livizos regarding Opposition to MSN's Request for Leave to file for Summary Judgment - re 238 Letter,. (Streifthau-Livizos, Michelle) (Entered: 12/02/2022) (5) |
| Nov 29, 2022 | 244 | Joint STIPULATION TO EXTEND TIME Sur Reply Expert Reports to December 13, 2022 - filed by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 11/29/2022) (3) |
| Nov 28, 2022 | 242 | NOTICE OF SERVICE of [HIGHLY CONFIDENTIAL] Reply Expert Report of Peter A. Lewitt, M.D. filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) (Entered: 11/28/2022) (2) |
| Nov 28, 2022 | 243 | ORAL ORDER: Having reviewed Plaintiff Acadia Pharmaceuticals Inc.'s ("Plaintiff") letter, D.I. 239, IT IS HEREBY ORDERED that, no later than December 2, 2022, Plaintiff shall respond to Defendants MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc.'s (collectively, "Defendants") letter motion for leave to move for summary judgment of invalidity of U.S. Patent 7,601,740 (the '740 patent), D.I. 238. ORDERED by Judge Gregory B. Williams on 11/28/22. (ntl) (Entered: 11/28/2022) (0) |
| Nov 23, 2022 | 239 | Letter to The Honorable Gregory B. Williams from Michelle C. Streifthau-Livizos regarding response to MSN's letter motion for leave to move for summary judgment - re 238 Letter,. (Streifthau-Livizos, Michelle) (Entered: 11/23/2022) (1) |
| Nov 23, 2022 | 240 | NOTICE OF SERVICE of [HIGHLY CONFIDENTIAL] Reply Expert Report of Dr. Patrick Finley filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) (Entered: 11/23/2022) (2) |
| Nov 23, 2022 | 241 | NOTICE OF SERVICE of Defendants' Expert Report of Ivan T. Hofmann filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Myer, R.) (Entered: 11/23/2022) (2) |
| Nov 22, 2022 | 238 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment. (Attachments: # 1 Exhibit The Nuplazid Orange Book page, # 2 Exhibit Dr. Roths 10/28/2022 report, # 3 Exhibit C # 4 Exhibit A timeline of the relevant events)(Green, James) Modified on 11/22/2022 (ntl). (Entered: 11/22/2022) (Main Document) (4) |
| Nov 22, 2022 | 238 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment. (Attachments: # 1 Exhibit The Nuplazid Orange Book page, # 2 Exhibit Dr. Roths 10/28/2022 report, # 3 Exhibit C # 4 Exhibit A timeline of the relevant events)(Green, James) Modified on 11/22/2022 (ntl). (Entered: 11/22/2022) (Exhibit The Nuplazid Orange Book page) (3) |
| Nov 22, 2022 | 238 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment. (Attachments: # 1 Exhibit The Nuplazid Orange Book page, # 2 Exhibit Dr. Roths 10/28/2022 report, # 3 Exhibit C # 4 Exhibit A timeline of the relevant events)(Green, James) Modified on 11/22/2022 (ntl). (Entered: 11/22/2022) (Exhibit Dr. Roths 10/28/2022 report) (5) |
| Nov 22, 2022 | 238 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment. (Attachments: # 1 Exhibit The Nuplazid Orange Book page, # 2 Exhibit Dr. Roths 10/28/2022 report, # 3 Exhibit C # 4 Exhibit A timeline of the relevant events)(Green, James) Modified on 11/22/2022 (ntl). (Entered: 11/22/2022) (Exhibit Double Patenting Safe Harbor Statute, 35 U.S.C. § 121) (27) |
| Nov 22, 2022 | 238 | Letter to Honorable Gregory B. Williams from James S. Green, Jr. regarding Defendant MSNs Request to File Motion for Summary Judgment. (Attachments: # 1 Exhibit The Nuplazid Orange Book page, # 2 Exhibit Dr. Roths 10/28/2022 report, # 3 Exhibit C # 4 Exhibit A timeline of the relevant events)(Green, James) Modified on 11/22/2022 (ntl). (Entered: 11/22/2022) (Exhibit A timeline of the relevant events) (2) |
| Oct 31, 2022 | 237 | NOTICE OF SERVICE of Rebuttal Expert Report of Stuart H. Isaacson, M.D., F.A.A.N.; Rebuttal Expert Report of Dr. William Jorgensen; Rebuttal Expert Report of Professor Bryan L. Roth, M.D., Ph.D.; Expert Report of Sean D. Sheridan, Ph.D.; and Rebuttal Expert Report of Dennis M. Fisher, M.D. filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 10/31/2022) (3) |
| Sep 30, 2022 | 236 | STIPULATION Stay Claims and be Bound by Result in Litigation as to TEVA Pharmaceuticals USA Inc. by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) (Entered: 09/30/2022) (6) |
| Sep 9, 2022 | 229 | NOTICE OF SERVICE of [HIGHLY CONFIDENTIAL] Opening Expert Report of Dr. Patrick Finley filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) (Entered: 09/09/2022) (2) |
| Sep 9, 2022 | 230 | NOTICE OF SERVICE of Opening Expert Report of Stuart H. Isaacson, M.D. and Opening Report of Dr. William L. Jorgensen Regarding Zyduss Infringement of U.S. Patent No. 7,601,704 filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 09/09/2022) (2) |
| Sep 9, 2022 | 231 | NOTICE OF SERVICE of Opening Expert Report of Stuart H. Isaacson, M.D. and Opening Expert Report of Dr. William L. Jorgensen Regarding Aurobindos Infringement of U.S. Patent No. 7,601,740 filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 09/09/2022) (2) |
| Sep 9, 2022 | 232 | NOTICE requesting Clerk to remove Michael K. Nutter as co-counsel.. (Hoeschen, Nathan) (Entered: 09/09/2022) (1) |
| Sep 9, 2022 | 233 | NOTICE OF SERVICE of (1) Expert Report of Clayton H. Heathcock, Ph.D. (2) Opening Report of Peter A. LeWitt, M.D. on the Invalidity of U.S. Patent No. 7,659,285 filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) (Entered: 09/09/2022) (3) |
| Sep 9, 2022 | 234 | NOTICE OF SERVICE of Opening Expert Report of Stuart H. Isaacson, M.D. and Opening Report of Dr. William L. Jorgensen Regarding Tevas Infringement of U.S. Patent No. 7,601,704 filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 09/09/2022) (2) |
| Sep 9, 2022 | 235 | NOTICE OF SERVICE of Opening Report of Dr. William L. Jorgensen Regarding MSNs Infringement of U.S. Patent No. 7,601,704 filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) (Entered: 09/09/2022) (2) |
| Aug 22, 2022 | 228 | Joint Stipulation and Proposed Order to Extend Deadlines for Expert Reports, by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) Modified on 8/22/2022 (nms). (Entered: 08/22/2022) (3) |
| Jul 6, 2022 | 227 | Answer to Counterclaim (5) Docket Text: ANSWER to [215] Answer to Amended Complaint, and Counterclaims, by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) Modified on 7/6/2022 (nms). |
| Jun 29, 2022 | 226 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Charles E. Davis as co-counsel. Reason for request: No longer with the firm of Saul Ewing Arnstein & Lehr LLP. (Streifthau-Livizos, Michelle) |
| Jun 27, 2022 | 225 | Order (3) Docket Text: SO ORDERED Granting [224] Stipulation and Proposed Order Regarding Authenticity of ANDA No. 214782. Signed by Judge Richard G. Andrews on 6/27/2022. (nms) |
| Jun 24, 2022 | 219 | Stipulation (3) Docket Text: STIPULATION regarding authenticity of ANDA Nos. 214493 and 214502 by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) |
| Jun 24, 2022 | 220 | Order (3) Docket Text: SO ORDERED Granting [219] Stipulation regarding authenticity of ANDA Nos. 214493 and 214502. Signed by Judge Richard G. Andrews on 6/24/2022. (nms) |
| Jun 24, 2022 | 221 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1. Defendant Teva Pharmaceuticals USA, Inc.'s Amended Disclosures 2. Defendant Teva Pharmaceuticals USA, Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-8) filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Jun 24, 2022 | 222 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Amended Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Jun 24, 2022 | 223 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limiteds [HIGHLY CONFIDENTIAL] First Supplemental Invalidity Contentions for Patent Claims Asserted in Connection with Zyduss 10 MG Tablet Proposed ANDA Product filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) |
| Jun 24, 2022 | 224 | Stipulation (3) Docket Text: STIPULATION regarding authenticity of ANDA No. 214782 by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) |
| Jun 21, 2022 | 217 | Stipulation (3) Docket Text: STIPULATION regarding authenticity of ANDA No. 214750 by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) |
| Jun 21, 2022 | 218 | Order (3) Docket Text: SO ORDERED Granting [217] Stipulation and Proposed Order Regarding Authenticity of ANDA No. 214750. Signed by Judge Richard G. Andrews on 6/21/2022. (nms) |
| Jun 16, 2022 | 216 | Answer to Amended Complaint (29) Docket Text: ANSWER to [212] Amended Complaint, and Affirmative Defenses, by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) Modified on 6/16/2022 (nms). |
| Jun 15, 2022 | 215 | Answer to Amended Complaint (20) Docket Text: ANSWER to [207] Amended Complaint and COUNTERCLAIMS against ACADIA Pharmaceuticals Inc., by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited.(Myer, R.) Modified on 6/15/2022 (nms). |
| Jun 14, 2022 | 214 | Answer to Counterclaim (13) Docket Text: ANSWER to [197] Answer to Amended Complaint, and Counterclaims, by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) Modified on 6/14/2022 (nms). |
| Jun 13, 2022 | 213 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Supplemental Invalidity Contentions filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [208] MOTION for Pro Hac Vice Appearance of Attorney Sharon Lin, filed by Teva Pharmaceuticals USA, Inc.. Signed by Judge Richard G. Andrews on 6/2/2022. (nms) |
| Jun 2, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Sharon Lin for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jun 2, 2022 | 208 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Sharon Lin - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Jun 2, 2022 | 209 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc.'s [CONFIDENTIAL-PURSUANT TO PROTECTIVE ORDER] Objections and Reponses to Acadia's Rule 30(b)(6) Notice to Zydus filed by Zydus Pharmaceuticals (USA) Inc..(Bilson, David) |
| Jun 2, 2022 | 210 | Main Document (3) Docket Text: STIPULATION and Proposed Order Regarding Third Amended Complaint Against Zydus, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Amended Complaint, # (2) Red line version)(Streifthau-Livizos, Michelle) Modified on 6/2/2022 (nms). |
| Jun 2, 2022 | 210 | Third Amended Complaint (17) |
| Jun 2, 2022 | 210 | Red Line (18) |
| Jun 2, 2022 | 211 | Order (3) Docket Text: SO ORDERED Granting [210] Stipulation and Proposed Order Regarding Third Amended Complaint Against Zydus. Signed by Judge Richard G. Andrews on 6/2/2022. (nms) |
| Jun 2, 2022 | 212 | Main Document (17) Docket Text: THIRD Amended Complaint against Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.- filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G)(Streifthau-Livizos, Michelle) Modified on 6/3/2022 (nms). |
| Jun 2, 2022 | 212 | Exhibit A (30) |
| Jun 2, 2022 | 212 | Exhibit B (29) |
| Jun 2, 2022 | 212 | Exhibit C (23) |
| Jun 2, 2022 | 212 | Exhibit D (23) |
| Jun 2, 2022 | 212 | Exhibit E (24) |
| Jun 2, 2022 | 212 | Exhibit F (24) |
| Jun 2, 2022 | 212 | Exhibit G (23) |
| Jun 2, 2022 | 212 | Amended Complaint* (1) |
| Jun 1, 2022 | 205 | Main Document (3) Docket Text: STIPULATION and Proposed Order Regarding Second Amended Complaint Against Aurobindo, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Second Amended Complaint, # (2) Redline version)(Streifthau-Livizos, Michelle) Modified on 6/1/2022 (nms). |
| Jun 1, 2022 | 205 | Second Amended Complaint (14) |
| Jun 1, 2022 | 205 | Redline Second Amended Complaint (14) |
| Jun 1, 2022 | 206 | Order (3) Docket Text: SO ORDERED Granting [205] Stipulation and Proposed Order Regarding Second Amended Complaint Against Aurobindo. Signed by Judge Richard G. Andrews on 6/1/2022. (nms) |
| Jun 1, 2022 | 207 | Main Document (14) Docket Text: SECOND Amended Complaint against Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.- filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D)(Streifthau-Livizos, Michelle) Modified on 6/2/2022 (nms). |
| Jun 1, 2022 | 207 | Exhibit A (30) |
| Jun 1, 2022 | 207 | Exhibit B (29) |
| Jun 1, 2022 | 207 | Exhibit C (24) |
| Jun 1, 2022 | 207 | Exhibit D (24) |
| Jun 1, 2022 | 207 | Amended Complaint* (1) |
| May 31, 2022 | 204 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Objections to Acadia's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Myer, R.) |
| May 27, 2022 | 201 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Teva's Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| May 27, 2022 | 202 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Acadia Pharmaceuticals Inc.s Amended Infringement Contentions to Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) |
| May 27, 2022 | 203 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Acadia Pharmaceuticals Inc.s Amended Infringement Contentions to Teva Pharmaceuticals USA, Inc. filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [199] STIPULATION and Proposed Order to Extend Time to complete fact discovery for the sole purpose of completing depositions of fact witnesses to June 24, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. (nms) |
| May 26, 2022 | 199 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for the parties to complete fact discovery for the sole purpose of completing depositions of fact witnesses to June 24, 2022 - filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
| May 26, 2022 | 200 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Acadias Second Amended Responses and Objections to Defendants First and Second Set of Interrogatories (Nos. 2-3, 5, 6, 10, and 12) filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) |
| May 25, 2022 | 198 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiffs Objections and Responses to Defendants First Set of Request for Admissions (Nos. 1-11) filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) |
| May 24, 2022 | 197 | Answer to Amended Complaint (30) Docket Text: ANSWER to [188] Amended Complaint, COUNTERCLAIMS and Affirmative Defenses against ACADIA Pharmaceuticals Inc., by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) Modified on 5/24/2022 (nms). |
| May 23, 2022 | 195 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Acadia Pharmaceuticals Inc.s Objections and Responses to Defendants Second Set of Requests to Plaintiff for the Production of Documents and Things (No. 83) filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) |
| May 23, 2022 | 196 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Brendan Teehan on June 7, 2022 filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Myer, R.) |
| May 19, 2022 | 193 | Order (4) Docket Text: SO ORDERED Granting [191] Joint Stipulation and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,449,185, 10cv646,480, and 10,849,891. Signed by Judge Richard G. Andrews on 5/19/2022. (nms) |
| May 19, 2022 | 194 | Order (3) Docket Text: SO ORDERED Granting [192] Stipulation and Proposed Order Regarding Authenticity of IND No. 068384 and NDA Nos. 207318 and 210793. Signed by Judge Richard G. Andrews on 5/19/2022. (nms) |
| May 18, 2022 | 191 | Stipulation (4) Docket Text: STIPULATION non infringement of U.S. patent NOS 10,449,185; 10,646,480; and 10,849,891, by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) |
| May 18, 2022 | 192 | Stipulation (3) Docket Text: STIPULATION regarding authenticity of IND No. 068384 and NDA NOS. 207318 and 210793 by ACADIA Pharmaceuticals Inc.. (Streifthau-Livizos, Michelle) |
| May 11, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Felix A. Eyzaguirre for ACADIA Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| May 11, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The red-line version filed as an attachment at D.I. [188] has been removed. This was duplicative of a red-line already on file at D.I. [185]. (nms) |
| May 11, 2022 | 190 | Notice Requesting Removal of Co-Counsel (1) Docket Text: NOTICE requesting Clerk to remove Katherine D. Hundt as co-counsel.. (Hoeschen, Nathan) |
| May 10, 2022 | 188 | Main Document (11) Docket Text: SECOND Amended Complaint against Teva Pharmaceuticals USA, Inc.- filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (2) Exhibit A-D)(Streifthau-Livizos, Michelle) Modified on 5/11/2022 (nms). |
| May 10, 2022 | 188 | Exhibit A-D (105) |
| May 10, 2022 | 189 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Date of Expiration of Patent:. (Streifthau-Livizos, Michelle) |
| May 10, 2022 | 188 | Amended Complaint* (1) |
| May 9, 2022 | 187 | Order (3) Docket Text: SO ORDERED Granting [185] Stipulation and Proposed Order Regarding Second Amended Complaint Against Teva. Signed by Judge Richard G. Andrews on 5/9/2022. (nms) |
| May 6, 2022 | 185 | Main Document (3) Docket Text: STIPULATION and Proposed Order Regarding Second Amended Complaint, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Second Amended Complaint, # (2) Redline version)(Streifthau-Livizos, Michelle) Modified on 5/6/2022 (nms). |
| May 6, 2022 | 185 | Second Amended Complaint (11) |
| May 6, 2022 | 185 | Redline Second Amended Complaint (11) |
| May 6, 2022 | 186 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of MSNs Response and Objections to Defendants 30(b)(6) Deposition Notice filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| May 5, 2022 | 183 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Michelle Streifthau-Livizos on behalf of ACADIA Pharmaceuticals Inc. (Streifthau-Livizos, Michelle) |
| May 5, 2022 | 184 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's Amended 26(a)(1) Disclosures and Amended Disclosures Regarding Custodians and Non Custodial Data Sources filed by ACADIA Pharmaceuticals Inc..(Streifthau-Livizos, Michelle) |
| Apr 29, 2022 | 179 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Teva Pharmaceuticals USA, Inc. on TBD filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Apr 29, 2022 | 180 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Zydus Pharmaceuticals USA Inc. on TBD filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Apr 29, 2022 | 181 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. on TBD filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Apr 29, 2022 | 182 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Aurobindo Pharma Limited and Aurobindo Pharma USA on TBD filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Apr 27, 2022 | 178 | Order (5) Docket Text: SO ORDERED Granting [177] Stipulated Final Judgment and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,646,480 and 10,849,891 between ACADIA Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.. Signed by Judge Richard G. Andrews on 4/27/2022. (nms) |
| Apr 26, 2022 | 175 | Stipulation (4) Docket Text: STIPULATION and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,646,480 and 10,849,891, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 4/26/2022 (nms). |
| Apr 26, 2022 | 176 | Order (4) Docket Text: SO ORDERED Granting [175] Stipulation and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,646,480 and 10,849,891. Signed by Judge Richard G. Andrews on 4/26/2022. (nms) |
| Apr 26, 2022 | 177 | Stipulation (5) Docket Text: Proposed Stipulated Final Judgment and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,646,480 and 10,849,891, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 4/26/2022 (nms). |
| Apr 25, 2022 | 173 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Second Set of Requests to Plaintiff for the Production of Documents and Things (No. 83) filed by Zydus Lifesciences Limited, Zydus Pharmaceuticals (USA) Inc..(Bilson, David) |
| Apr 25, 2022 | 174 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' First Set of Requests for Admission to Plaintiff Acadia Pharmaceuticals Inc. filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Apr 22, 2022 | 171 | Stipulation (4) Docket Text: Joint Stipulation and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,646,480 and 10,849,891, by ACADIA Pharmaceuticals Inc.. (Morin, Aubrey) Modified on 4/22/2022 (nms). |
| Apr 22, 2022 | 172 | Order (4) Docket Text: SO ORDERED Granting [171] Joint Stipulation and Proposed Order of Non-Infringement of U.S. Patent Nos. 10,646,480 and 10,849,891. Signed by Judge Richard G. Andrews on 4/22/2022. (nms) |
| Apr 21, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [170] MOTION for Pro Hac Vice Appearance of Attorney Felix Eyzaguirre, filed by ACADIA Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 4/21/2022. (nms) |
| Apr 21, 2022 | 170 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Felix Eyzaguirre - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Certification of Felix Eyzaguirre)(Morin, Aubrey) |
| Apr 21, 2022 | 170 | Certification of Felix Eyzaguirre (1) |
| Apr 20, 2022 | 167 | Main Document (3) Docket Text: Unopposed Motion to Change Name of Defendant Cadila Healthcare Limited to Zydus Lifesciences Limited - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Proposed Order)(Bilson, David) Modified on 4/20/2022 (nms). |
| Apr 20, 2022 | 167 | Proposed Order (2) |
| Apr 20, 2022 | 168 | Notice to Take Deposition (11) Docket Text: NOTICE to Take Deposition of Plaintiff Acadia Pharmaceuticals, Inc. on a Date, Time and Place Mutually Agreed Upon By Counsel Pursuant to Federal Rule of Civil Procedure 30(b)(6) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 20, 2022 | 169 | Order (2) Docket Text: ORDER Granting [167] Unopposed Motion to Change Name of Defendant Cadila Healthcare Limited to Zydus Lifesciences Limited. Signed by Judge Richard G. Andrews on 4/20/2022. (nms) |
| Apr 14, 2022 | 153 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Stephen Abele on May 20, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 154 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Rajesh Agarwal on May 26, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 155 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Carl-Magnus Andersson on May 25, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 156 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Ethan Burstein on May 10, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 157 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Robert Davis on May 24, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 158 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Daryl DeKarske on May 26, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 159 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Uli Hacksell on May 3, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 160 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Charmain Lykins on May 9, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 161 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Amanda Morgan on May 2, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 162 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Andrew Parkinson on May 19, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 163 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Ravi Tejwani on May 13, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 164 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Allan Uldam on May 18, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 165 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Emanuel Vizzotti on May 6, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 14, 2022 | 166 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of David Weiner on May 17, 2022 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 6, 2022 | 152 | Memorandum Opinion (13) Docket Text: MEMORANDUM OPINION providing claim construction for multiple terms in U.S. Patent Nos. 10,449,185; 10,646,480; 10,849,891. Signed by Judge Richard G. Andrews on 4/6/2022. (nms) |
| Apr 1, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Fallon for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (lih) |
| Mar 31, 2022 | 151 | Order (3) Docket Text: SO ORDERED Granting [150] Stipulation and Proposed Order of Dismissal of Certain Claims, Counterclaims, and Defenses. Signed by Judge Richard G. Andrews on 3/31/2022. (nms) |
| Mar 30, 2022 | 150 | Stipulation of Dismissal (3) Docket Text: STIPULATION and Proposed Order of Dismissal of Certain Claims, Counterclaims, and Defenses, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 3/31/2022 (nms). |
| Mar 22, 2022 | 148 | Stipulation of Dismissal (3) Docket Text: STIPULATION of Dismissal of Certain Claims, Counterclaims, and Defenses, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 3/22/2022 (nms). |
| Mar 22, 2022 | 149 | Order (3) Docket Text: SO ORDERED Granting [148] Stipulation and Proposed Order of Dismissal of Certain Claims, Counterclaims, and Defenses. Signed by Judge Richard G. Andrews on 3/22/2022. (nms) |
| Mar 10, 2022 | 146 | Stipulation (3) Docket Text: STIPULATION Dismissal of Certain Claims, Counterclaims, and Defenses by ACADIA Pharmaceuticals Inc.. (Taylor, James) |
| Mar 10, 2022 | 147 | Order (3) Docket Text: SO ORDERED Granting [146] Stipulation of Dismissal of Certain Claims, Counterclaims, and Defenses. Signed by Judge Richard G. Andrews on 3/10/2022. (nms) |
| Mar 2, 2022 | 145 | Transcript (75) Docket Text: Official Transcript of Markman Hearing held on 2/23/22 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/23/2022. Redacted Transcript Deadline set for 4/4/2022. Release of Transcript Restriction set for 5/31/2022. (Triozzi, Heather) |
| Mar 1, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [143] MOTION for Pro Hac Vice Appearance of Attorney August M. Melcher, filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Signed by Judge Richard G. Andrews on 3/1/2022. (nms) |
| Mar 1, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney August M. Melcher for Cadila Healthcare Limited and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Mar 1, 2022 | 143 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney August M. Melcher - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Certification of August M. Melcher)(Bilson, David) |
| Mar 1, 2022 | 143 | Certification of August M. Melcher (1) |
| Mar 1, 2022 | 144 | Order (3) Docket Text: SO ORDERED Granting [142] Stipulation and Proposed Order of Dismissal of Certain Claims, Counterclaims, and Defenses. Signed by Judge Richard G. Andrews on 3/1/2022. (nms) |
| Feb 28, 2022 | 142 | Stipulation of Dismissal (3) Docket Text: STIPULATION of Dismissal of Certain Claims, Counterclaims, and Defenses, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 3/1/2022 (nms). |
| Feb 23, 2022 | N/A | Markman Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Markman Hearing held on 2/23/2022. Counsel for Plaintiff: J. Taylor. Counsel for Defendants: N. Hoeschen, J. Green, D. Bilson. (Court Reporter Heather Triozzi.) (lak) |
| Feb 11, 2022 | 141 | Notice Requesting Removal of Co-Counsel (1) Docket Text: NOTICE requesting Clerk to remove Christopher J. Cassella as co-counsel. Reason for request: No Longer with Firm. (Bilson, David) |
| Feb 1, 2022 | 140 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's Amended Responses and Objections to Defendants' First and Second Set of Interrogatories filed by ACADIA Pharmaceuticals Inc..(Morin, Aubrey) |
| Jan 31, 2022 | 139 | Order (3) Docket Text: SO ORDERED Granting [136] Joint Motion for Hearing on Claim Construction. Signed by Judge Richard G. Andrews on 1/31/2022. (nms) |
| Jan 28, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The appendix filed as an attachment to the brief at D.I. 137 has been removed. Briefs and appendices are to be filed independent of each other. Counsel shall refile the appendix accordingly. (nms) |
| Jan 28, 2022 | 136 | Motion for Hearing (3) Docket Text: Joint Motion for Hearing on Claim Construction - filed by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 1/28/2022 (nms). |
| Jan 28, 2022 | 137 | Joint Claim Construction Brief (30) Docket Text: JOINT Claim Construction Brief, filed by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 1/28/2022 (nms). |
| Jan 28, 2022 | 138 | Appendix (30) Docket Text: Joint Appendix re [137] Joint Claim Construction Brief, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 1/31/2022 (nms). |
| Jan 21, 2022 | 135 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Sur-Reply Claim Construction Brief filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Myer, R.) |
| Dec 20, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Michael P. Hogan for Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Dec 6, 2021 | 134 | Notice (Other) (1) Docket Text: NOTICE of Withdrawal of Kenneth L. Dorsney, Cortlan S. Hitch and Morris James LLP for Aurobindo by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. (Dorsney, Kenneth) |
| Dec 1, 2021 | 133 | Order (3) Docket Text: SO ORDERED Granting [132] Stipulation and Proposed Order of Dismissal of Certain Claims, Counterclaims, and Defenses. Signed by Judge Richard G. Andrews on 12/1/2021. (nms) |
| Nov 30, 2021 | 132 | Stipulation of Dismissal (3) Docket Text: STIPULATION and Proposed Order of Dismissal of Certain Claims, Counterclaims, and Defenses, by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) Modified on 11/30/2021 (nms). |
| Nov 29, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Timothy H. Kratz for Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Nov 24, 2021 | 131 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's Responses and Objections to Interrogatories Nos 11-12 filed by ACADIA Pharmaceuticals Inc..(Morin, Aubrey) |
| Nov 18, 2021 | 130 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by R. Touhey Myer on behalf of Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. (Myer, R.) |
| Oct 26, 2021 | 129 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Second Set of Interrogatories filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Oct 18, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [128] MOTION for Pro Hac Vice Appearance of Attorney Michael P. Hogan, filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited. Signed by Judge Richard G. Andrews on 10/18/2021. (nms) |
| Oct 18, 2021 | 128 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael P. Hogan - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Oct 12, 2021 | 127 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's Opening Claim Construction Brief filed by ACADIA Pharmaceuticals Inc..(Morin, Aubrey) |
| Oct 1, 2021 | 126 | Answer to Counterclaim (9) Docket Text: ANSWER to [124] Answer to Amended Complaint, and Counterclaims, by ACADIA Pharmaceuticals Inc..(Taylor, James) Modified on 10/4/2021 (nms). |
| Sep 10, 2021 | 124 | Main Document (38) Docket Text: ANSWER to [121] Second Amended Complaint, and COUNTERCLAIMS against ACADIA Pharmaceuticals Inc., by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Phillips, John) Modified on 9/10/2021 (nms). Modified on 9/10/2021 (nms). |
| Sep 10, 2021 | 124 | Exhibit A (29) |
| Sep 10, 2021 | 124 | Exhibit B (35) |
| Sep 10, 2021 | 125 | Main Document (8) Docket Text: Joint Claim Construction Chart, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Exhibit L, # (13) Exhibit M, # (14) Exhibit N, # (15) Exhibit O, # (16) Exhibit P, # (17) Exhibit Q, # (18) Exhibit R)(Taylor, James) Modified on 9/13/2021 (nms). |
| Sep 10, 2021 | 125 | Exhibit A (23) |
| Sep 10, 2021 | 125 | Exhibit B (24) |
| Sep 10, 2021 | 125 | Exhibit C (24) |
| Sep 10, 2021 | 125 | Exhibit D (6) |
| Sep 10, 2021 | 125 | Exhibit E (7) |
| Sep 10, 2021 | 125 | Exhibit F (3) |
| Sep 10, 2021 | 125 | Exhibit G (8) |
| Sep 10, 2021 | 125 | Exhibit H (10) |
| Sep 10, 2021 | 125 | Exhibit I (8) |
| Sep 10, 2021 | 125 | Exhibit J (8) |
| Sep 10, 2021 | 125 | Exhibit K (8) |
| Sep 10, 2021 | 125 | Exhibit L (8) |
| Sep 10, 2021 | 125 | Exhibit M (9) |
| Sep 10, 2021 | 125 | Exhibit N (4) |
| Sep 10, 2021 | 125 | Exhibit O (9) |
| Sep 10, 2021 | 125 | Exhibit P (8) |
| Sep 10, 2021 | 125 | Exhibit Q (7) |
| Sep 10, 2021 | 125 | Exhibit R (8) |
| Aug 27, 2021 | 121 | Main Document (16) Docket Text: SECOND Amended Complaint against Cadila Healthcare Limited, Zydus Healthcare (USA) LLC- filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) black line version, # (2) Exhibits A-G)(Taylor, James) Modified on 8/27/2021 (nms). |
| Aug 27, 2021 | 121 | Exhibit Comparison version (16) |
| Aug 27, 2021 | 121 | Exhibit A-G (186) |
| Aug 27, 2021 | 122 | Main Document (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,517,860 ;10,646,480 ;10,953,000 ;10,849,891 . (Attachments: # (1) Page 2-AO 120)(Taylor, James) |
| Aug 27, 2021 | 122 | Page 2-AO 120 (1) |
| Aug 27, 2021 | 123 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: July 20, 2021. Date of Expiration of Patent: March 23, 2037.Thirty Month Stay Deadline: 10/29/2023. (Taylor, James) |
| Aug 27, 2021 | 121 | Amended Complaint* (1) |
| Aug 26, 2021 | 120 | Order (2) Docket Text: SO ORDERED Granting [119] Stipulation and Proposed Order Regarding Second Amended Complaint Against Zydus. Signed by Judge Richard G. Andrews on 8/26/2021. (nms) |
| Aug 25, 2021 | 119 | Main Document (2) Docket Text: STIPULATION and Proposed Order Regarding Second Amended Complaint Against Zydus, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Taylor, James) Modified on 8/26/2021 (nms). |
| Aug 25, 2021 | 119 | Exhibit 1-Second Ameded Complaint (203) |
| Aug 25, 2021 | 119 | Exhibit 2-Comparison version of Second Amended Complaint (17) |
| Aug 11, 2021 | 118 | Order (6) Docket Text: SO ORDERED Granting [117] Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 8/11/2021. (nms) |
| Aug 10, 2021 | 117 | Stipulation (6) Docket Text: STIPULATION and Proposed Order regarding claim construction, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 8/10/2021 (nms). |
| Aug 3, 2021 | 116 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's Proposed Terms for Construction filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Aug 2, 2021 | 115 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants' Preliminary Disclosure of Claims for Construction filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Jun 21, 2021 | 113 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's responses to Plaintiff's Third Set of Requests for Production (No. 68) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Jun 21, 2021 | 114 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's responses to Plaintiff's Fourth Set of Requests for Production (No. 69) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Jun 18, 2021 | 110 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of MSN's Objections and Responses to Plaintiff's Third Set of Requests for Production (No. 67) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Jun 18, 2021 | 111 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Teva Pharmaceuticals USA, Inc.'s Responses and Objections to Plaintiff's Third Set of Request for the Production of Documents and Things (No. 69) filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jun 18, 2021 | 112 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limiteds [HIGHLY CONFIDENTIAL INFORMATION -OUTSIDE COUNSELs EYES ONLY] Objections and Responses to Plaintiffs Third Set of Requests for the Production of Documents and Things (No. 68) filed by Cadila Healthcare Limited, Zydus Healthcare (USA) LLC.(Bilson, David) |
| Jun 11, 2021 | 108 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Responses and Objections to MSN's First Set of Requests for Production and First Set of Interrogatories filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Jun 11, 2021 | 109 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's Responses and Objections to Defendants' First Set of Requests for Production and Interrogatories filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Jun 4, 2021 | 104 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of MSN's Objections and Responses to Plaintiff's Second Set of Requests for Production (No. 66) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Jun 4, 2021 | 105 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Teva Pharmaceuticals USA, Inc.'s Responses and Objections to Plaintiff's Second Set of Requests for the Production of Documents and Things (Nos. 66-68) filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Jun 4, 2021 | 106 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's [HIGHLY CONFIDENTIAL INFORMATION -OUTSIDE COUNSEL'S EYES ONLY] Objections and Responses to Plaintiff's Second Set of Requests for the Production of Documents and Things (NOS. 66-67) filed by Cadila Healthcare Limited, Zydus Healthcare (USA) LLC.(Bilson, David) |
| Jun 4, 2021 | 107 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Responses and Objections to Plaintiffs' Second Set of Requests for Production of Documents and Things (Nos. 66-67) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| May 24, 2021 | 103 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Fourth Set of Requests for Production directed to Aurobindo filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 20, 2021 | 99 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Third Request for Production (No. 68) upon Zydus Pharmaceuticals and Cadila Healthcare Limited filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 20, 2021 | 100 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Third Request for Production (No. 69) directed to Teva Pharmaceuticals USA filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 20, 2021 | 101 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Third Request for Production (No. 67) upon MSN Laboratories and MSN Pharmaceuticals filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 20, 2021 | 102 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Third Request for Production (No. 68) upon Aurobindo Pharma Limited and Aurobindo Pharma USA filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 13, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The docket text and linking for D.I. [95] and D.I. [96] have been corrected. The filings were linked to Answers they were not in reference to. (nms) |
| May 13, 2021 | 97 | Statement (9) Docket Text: ANSWER to [81] Answer to Amended Complaint, and Counterclaims, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 5/13/2021 (nms). |
| May 13, 2021 | 98 | Statement (5) Docket Text: ANSWER to [80] Answer to Amended Complaint, and Counterclaims, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 5/13/2021 (nms). |
| May 12, 2021 | 96 | Answer to Counterclaim (16) Docket Text: ANSWER to [79] Answer to Amended Complaint, and Counterclaims, by ACADIA Pharmaceuticals Inc..(Taylor, James) Modified on 5/13/2021 (nms). Modified on 5/13/2021 (nms). |
| May 11, 2021 | 93 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants' First Set of Interrogatories and First Set of Requests to Plaintiff for Production of Documents filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| May 11, 2021 | 94 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendant MSN's First Set of Interrogatories and First Set of Requests for Admission to Plaintiff filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| May 11, 2021 | 95 | Answer to Counterclaim (12) Docket Text: ANSWER to [77] Answer to Amended Complaint, and Counterclaim, by ACADIA Pharmaceuticals Inc..(Taylor, James) Modified on 5/12/2021 (nms). Modified on 5/13/2021 (nms). |
| May 6, 2021 | 89 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Second Set of Requests for Production Nos. 66-67 directed to Zydus Pharmaceuticals (USA) Inc. filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 6, 2021 | 90 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Second Set of Requests for Production Nos. 66-68 directed to Teva Pharmaceuticals USA Inc. filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 6, 2021 | 91 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Second Set of Requests for Production No. 66 directed to MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc. filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 6, 2021 | 92 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Second Set of Requests for Production Nos. 66-67 directed to Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| May 3, 2021 | 87 | Stipulation of Dismissal (2) Docket Text: STIPULATION of Dismissal as to Hetero defendants only, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 5/3/2021 (nms). |
| May 3, 2021 | 88 | Order (2) Docket Text: SO ORDERED Granting [87] Stipulation of Dismissal (*Parties Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit-V terminated). Signed by Judge Richard G. Andrews on 5/3/2021. (nms) |
| Apr 29, 2021 | 86 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Initial Invalidity Contentions filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Apr 27, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [85] STIPULATION and Proposed Order Regarding to Hetero's Invalidity Contentions. Signed by Judge Richard G. Andrews on 4/27/2021. (nms) |
| Apr 26, 2021 | 84 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Initial Invalidity Contentions filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Apr 26, 2021 | 85 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to serve Hetero's Rule 4.d Invalidity Contentions to May 10, 2021 - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Golden, Ronald) |
| Apr 22, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The patent/trademark report filed as an exhibit to D.I. [81] has been removed from that filing. Defendants Zydus Healthcare (USA) LLC, Cadila Healthcare Limited are to refile this using the appropriate filing code thereby allowing the Patent Office to get notice. (nms) |
| Apr 22, 2021 | 80 | Answer to Amended Complaint (18) Docket Text: ANSWER to [70] Amended Complaint and COUNTERCLAIMS against All Plaintiffs, by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited.(Dorsney, Kenneth) Modified on 4/22/2021 (nms). |
| Apr 22, 2021 | 81 | Main Document (36) Docket Text: ANSWER to [67] Amended Complaint, Affirmative Defenses and COUNTERCLAIMS against ACADIA Pharmaceuticals Inc. by Zydus Healthcare (USA) LLC, Cadila Healthcare Limited. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Phillips, John) Modified on 4/22/2021 (nms). |
| Apr 22, 2021 | 81 | Exhibit A (29) |
| Apr 22, 2021 | 81 | Exhibit B (35) |
| Apr 22, 2021 | 82 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,659,285 ;7,923,564 . (Phillips, John) |
| Apr 22, 2021 | 83 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Aurobindo's Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-8) and; (2) Aurobindo's Responses and Objections to Plaintiff's First Set of Requests for Production (Nos. 1-65) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Apr 21, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [78] STIPULATION and Proposed Order Regarding Answer to First Amended Complaint (*Reset Answer Deadlines: Hetero Labs Limited answer due 5/21/2021; Hetero Labs Limited Unit-V answer due 5/21/2021; Hetero USA Inc. answer due 5/21/2021). Signed by Judge Richard G. Andrews on 4/21/2021. (nms) |
| Apr 21, 2021 | 78 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Hetero's Answer to Plaintiff's First Amended Complaint to May 21, 2021 - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Golden, Ronald) |
| Apr 21, 2021 | 79 | Answer to Amended Complaint (30) Docket Text: ANSWER to [61] Amended Complaint and COUNTERCLAIMS against ACADIA Pharmaceuticals Inc., by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) Modified on 4/21/2021 (nms). |
| Apr 20, 2021 | 77 | Answer to Amended Complaint (30) Docket Text: ANSWER to [58] Second Amended Complaint, and COUNTERCLAIMS against All Plaintiffs, by MSN Pharmaceuticals, Inc., MSN Laboratories Private Limited.(Green, James) Modified on 4/20/2021 (nms). |
| Apr 15, 2021 | 73 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Teva Pharmaceuticals USA, Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-8) (2) Defendant Teva Pharmaceuticals USA, Inc.'s Responses and Objections to Plaintiff's First Set of Requests for the Production of Documents and Things (Nos. 1-65) filed by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) |
| Apr 15, 2021 | 74 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc.'s Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-7) and Defendant Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc.'s Objections and Responses to Plaintiff's First Set of Requests for the Production of Documents and Things (Nos. 1-65) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Golden, Ronald) |
| Apr 15, 2021 | 75 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-10); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Requests for the Production of Documents and Things (Nos. 1-65) filed by Cadila Healthcare Limited, Zydus Healthcare (USA) LLC.(Bilson, David) |
| Apr 15, 2021 | 76 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants MSN Laboratories Private Limited and MSN Pharmaceutical, Inc.'s Objections and Responses to Plaintiffs First Set of Interrogatories and First Set of Requests for the Production of Documents filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Apr 9, 2021 | 70 | Main Document (13) Docket Text: FIRST Amended Complaint against Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Redline version, # (2) Exhibits A-E)(Taylor, James) Modified on 4/9/2021 (nms). |
| Apr 9, 2021 | 70 | Exhibit Redline (13) |
| Apr 9, 2021 | 70 | Exhibit A-E (135) |
| Apr 9, 2021 | 71 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 1/15/2021. Date of Expiration of Patent: 8/27/2038.Thirty Month Stay Deadline: 10/29/2023. (Taylor, James) |
| Apr 9, 2021 | 72 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,646,480 ;10,849,891 . (Taylor, James) |
| Apr 9, 2021 | 70 | Amended Complaint* (1) |
| Apr 8, 2021 | 64 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) for MSN - Date Patentee(s) Received Notice: na. Date of Expiration of Patent: 8/27/2038.Thirty Month Stay Deadline: 10/29/2023. (Taylor, James) Modified on 4/9/2021 (nms). |
| Apr 8, 2021 | 65 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) for Hetero - Date Patentee(s) Received Notice: na. Date of Expiration of Patent: 8/27/2038.Thirty Month Stay Deadline: 10/29/2023. (Taylor, James) Modified on 4/9/2021 (nms). |
| Apr 8, 2021 | 66 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) for Teva - Date Patentee(s) Received Notice: 12/23/2020. Date of Expiration of Patent: 8/27/2038.Thirty Month Stay Deadline: 10/29/2023. (Taylor, James) Modified on 4/9/2021 (nms). |
| Apr 8, 2021 | 67 | Main Document (16) Docket Text: FIRST Amended Complaint against Cadila Healthcare Limited, Zydus Healthcare (USA) LLC - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Redline version, # (2) Exhibits A-F)(Taylor, James) |
| Apr 8, 2021 | 67 | Exhibit Redline (16) |
| Apr 8, 2021 | 67 | Exhibit A-F (158) |
| Apr 8, 2021 | 68 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) for Zydus - Date Patentee(s) Received Notice: 2/17/2021. Date of Expiration of Patent: 8/27/20387.Thirty Month Stay Deadline: 10/29/2023. (Taylor, James) Modified on 4/8/2021 (nms). Modified on 4/9/2021 (nms). |
| Apr 8, 2021 | 69 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,517,860 ;10,646,480 ;10,849,891 . (Taylor, James) |
| Apr 7, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The supplemental information forms filed at D.I. 56 and D.I. 59 have been removed per counsel's request. More complete supplemental forms will be refiled. (nms) |
| Apr 7, 2021 | 55 | Main Document (13) Docket Text: FIRST Amended Complaint against Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.- filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibits A-D)(Taylor, James) Modified on 4/7/2021 (nms). |
| Apr 7, 2021 | 55 | Exhibit 1 red line (14) |
| Apr 7, 2021 | 55 | Exhibit A-D (98) |
| Apr 7, 2021 | 57 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;10,449,185 ;10,646,480 ;10,849,891 . (Taylor, James) |
| Apr 7, 2021 | 58 | Main Document (12) Docket Text: SECOND Amended Complaint against MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc. - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibits A-D)(Taylor, James) Modified on 4/7/2021 (nms). |
| Apr 7, 2021 | 58 | Exhibit 1 red line (12) |
| Apr 7, 2021 | 58 | Exhibit A-D (113) |
| Apr 7, 2021 | 60 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,732,615 ;10,646,480 ;7,601,740 ;10,849,891 . (Taylor, James) |
| Apr 7, 2021 | 61 | Main Document (10) Docket Text: FIRST Amended Complaint against Teva Pharmaceuticals USA, Inc.- filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibits A-E)(Taylor, James) Modified on 4/7/2021 (nms). |
| Apr 7, 2021 | 61 | Exhibit Redline (13) |
| Apr 7, 2021 | 61 | Exhibit A-E (135) |
| Apr 7, 2021 | 62 | Order (2) Docket Text: SO ORDERED Granting [54] Stipulation and Proposed Order Regarding First Amended Complaint Against Aurobindo. Signed by Judge Richard G. Andrews on 4/7/2021. (nms) |
| Apr 7, 2021 | 63 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,646,480 ;10,849,891 . (Taylor, James) |
| Apr 7, 2021 | 55 | Amended Complaint* (1) |
| Apr 7, 2021 | 61 | Amended Complaint* (1) |
| Apr 7, 2021 | 58 | Amended Complaint* (1) |
| Apr 6, 2021 | 53 | Order (2) Docket Text: SO ORDERED Granting [52] Stipulation and Proposed Order Regarding First Amended Complaint Against Zydus. Signed by Judge Richard G. Andrews on 4/6/2021. (nms) |
| Apr 6, 2021 | 54 | Main Document (2) Docket Text: STIPULATION and Proposed Order Regarding First Amended Complaint Against Aurobindo, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Taylor, James) Modified on 4/6/2021 (nms). |
| Apr 6, 2021 | 54 | Exhibit 1 (148) |
| Apr 6, 2021 | 54 | Exhibit 2 (14) |
| Apr 5, 2021 | 49 | Order (2) Docket Text: SO ORDERED Granting [46] Stipulation and Proposed Order Regarding Second Amended Complaint Against MSN. Signed by Judge Richard G. Andrews on 4/5/2021. (nms) |
| Apr 5, 2021 | 50 | Order (2) Docket Text: SO ORDERED Granting [47] Stipulation and Proposed Order Regarding First Amended Complaint Against Hetero. Signed by Judge Richard G. Andrews on 4/5/2021. (nms) |
| Apr 5, 2021 | 51 | Order (2) Docket Text: SO ORDERED Granting [48] Stipulation and Proposed Order Regarding First Amended Complaint Against Teva. Signed by Judge Richard G. Andrews on 4/5/2021. (nms) |
| Apr 5, 2021 | 52 | Main Document (2) Docket Text: STIPULATION and Proposed Order Regarding First Amended Complaint Against Zydus, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Taylor, James) Modified on 4/5/2021 (nms). |
| Apr 5, 2021 | 52 | Exhibit 1 (174) |
| Apr 5, 2021 | 52 | Exhibit 2 (17) |
| Apr 2, 2021 | 46 | Main Document (2) Docket Text: STIPULATION and Proposed Order Regarding Second Amended Complaint Against MSN, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Taylor, James) Modified on 4/5/2021 (nms). |
| Apr 2, 2021 | 46 | Exhibit 1 (125) |
| Apr 2, 2021 | 46 | Exhibit 2 (13) |
| Apr 2, 2021 | 47 | Main Document (2) Docket Text: STIPULATION and Proposed Order Regarding First Amended Complaint Against Hetero, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Taylor, James) Modified on 4/5/2021 (nms). |
| Apr 2, 2021 | 47 | Exhibit 1 (111) |
| Apr 2, 2021 | 47 | Exhibit 2 (15) |
| Apr 2, 2021 | 48 | Main Document (2) Docket Text: STIPULATION and Proposed Order Regarding First Amended Complaint Against Teva, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2)(Taylor, James) Modified on 4/5/2021 (nms). |
| Apr 2, 2021 | 48 | Exhibit 1 (145) |
| Apr 2, 2021 | 48 | Exhibit 2 (14) |
| Mar 26, 2021 | 45 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Revised Infringement Contensions served upon MSN Laboratories filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 17, 2021 | 40 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories and Requests for Production served upon MSN Laboratories filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 17, 2021 | 41 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories and Request for Production served upon Hetero Labs Limited filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 17, 2021 | 42 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories and Request for Production served upon Zydus Pharmaceuticals Inc. filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 17, 2021 | 43 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories and Request for Production served upon Teva Pharmaceuticals filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 17, 2021 | 44 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Interrogatories and Request for Production served upon Aurobindo Pharma Limited filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 12, 2021 | 35 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions/Aurobindo Pharma filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 12, 2021 | 36 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions/MSN Pharmaceutical filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 12, 2021 | 37 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions/Zydus Pharma/Cadila Healthcare filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 12, 2021 | 38 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions/Teva Pharmaceuticals filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Mar 12, 2021 | 39 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions/Hetero Labs filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Feb 11, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Megan E. Christner for Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
| Feb 10, 2021 | 31 | Order (30) Docket Text: SO ORDERED Granting [30] Proposed Stipulated Protective Order. Signed by Judge Richard G. Andrews on 2/9/2021. (nms) |
| Feb 10, 2021 | 32 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants MSN Laboratories Private Limited and MSN Pharmaceutical, Inc.'s core technical documents filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Feb 10, 2021 | 33 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Core Technical Documents filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Feb 10, 2021 | 34 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Hetero Labs Limited, Hetero Labs Limites Unit-V, and Hetero USA Inc.'s Core Technical Documents, bearing bates numbers HETPIMA_00000001-HETPIMA_00016832 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Brauerman, Stephen) |
| Feb 9, 2021 | 30 | Stipulation (30) Docket Text: Proposed Stipulated Protective Order, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 2/9/2021 (nms). |
| Feb 8, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [29] STIPULATION and Proposed Order to Extend Time to file and application for a protection order to February 9, 2021. Signed by Judge Richard G. Andrews on 2/8/2021. (nms) |
| Feb 8, 2021 | 29 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION and Proposed Order to Extend Time - filed by Teva Pharmaceuticals USA, Inc.. (nms) |
| Feb 1, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [28] STIPULATION and Proposed Order to Extend Time to file application for protective order to 2/5/2021. Signed by Judge Richard G. Andrews on 2/1/2021. (nms) |
| Jan 29, 2021 | 28 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME to file application for protective order to 2/5/2021 - filed by ACADIA Pharmaceuticals Inc.. (Taylor, James) |
| Jan 18, 2021 | 27 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's [CONFIDENTIAL] Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's [CONFIDENTIAL] Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Cadila Healthcare Limited, Zydus Healthcare (USA) LLC.(Bilson, David) |
| Jan 15, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Rebecca A. Hilgar for ACADIA Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam) |
| Jan 13, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [26] MOTION for Pro Hac Vice Appearance of Attorney Rebecca A. Hilgar, filed by ACADIA Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 1/13/2021. (nms) |
| Jan 13, 2021 | 26 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Rebecca A. Hilgar - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Certification of Counsel)(Taylor, James) |
| Jan 13, 2021 | 26 | Certification of Counsel (1) |
| Jan 12, 2021 | 25 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Hetero Labs Limited, Hetero Labs Limites Unit-V, and Hetero USA Inc.'s Initial Disclosures Under Paragraph 3 of the Default Standard for Discovery and Defendants Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc.'s Initial Dislosures Under Rule 26(a)(1) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Brauerman, Stephen) |
| Jan 11, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [22] STIPULATION and Proposed Order to Extend Time to serve Initial Disclosures to January 18, 2021. Signed by Judge Richard G. Andrews on 1/11/2021. (nms) |
| Jan 11, 2021 | 20 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Aurobindo's Rule 26(a)(1) Initial Disclosures; and (2) Aurobindo's Paragraph 3 Disclosures filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Jan 11, 2021 | 21 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1. Defendant Teva Pharmaceuticals USA, Inc.'s Initial Disclosures 2. Defendant Teva Pharmaceuticals USA, Inc.'s Initial Disclosure of Electronically Stored Information filed by Teva Pharmaceuticals USA, Inc..(Keller, Karen) |
| Jan 11, 2021 | 22 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to serve Initial Disclosures to January 18, 2021 - filed by Cadila Healthcare Limited, Zydus Healthcare (USA) LLC. (Phillips, John) |
| Jan 11, 2021 | 23 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Rule 26(a) disclosures, Paragraph 3 Disclosures and Paragraph 4(a) Disclosures of Acadia filed by ACADIA Pharmaceuticals Inc..(Taylor, James) |
| Jan 11, 2021 | 24 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Rule 26(a)(1) Initial Disclosures and Defendants' Paragraph 3 Initial Disclosures filed by MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc..(Green, James) |
| Dec 10, 2020 | 19 | Statement (12) Docket Text: ANSWER to MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc's Counterclaims, by ACADIA Pharmaceuticals Inc.. (Taylor, James) Modified on 12/10/2020 (nms). |
| Dec 8, 2020 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Sherry R. Fallon for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:20-cv-00985-RGA, 1:20-cv-00986-RGA, 1:20-cv-01021-RGA, 1:20-cv-01022-RGA, 1:20-cv-01029-RGA(cak) |
| Dec 8, 2020 | 16 | Main Document (12) Docket Text: PROPOSED Scheduling Order, by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Letter)(Taylor, James) Modified on 12/8/2020 (nms). |
| Dec 8, 2020 | 16 | Letter (1) |
| Dec 8, 2020 | 17 | Scheduling Order (12) Docket Text: SCHEDULING ORDER: The above-captioned cases shall be consolidated under the first-filed action 20cv985-RGA. Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 4/8/2022. Amended Pleadings due by 6/13/2022. Fact Discovery completed by 5/26/2022. Joint Claim Construction Brief due by 1/28/2022. A Markman Hearing is set for 2/23/2022, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 4/21/2023, at 9:00 AM in Courtroom 6A. A 3 day Bench Trial is set to start 5/15/2023, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 12/8/2020. Associated Cases: 1:20-cv-00985-RGA, 1:20-cv-00986-RGA, 1:20-cv-01021-RGA, 1:20-cv-01022-RGA, 1:20-cv-01029-RGA(nms) |
| Dec 8, 2020 | N/A | Oral Order (0) Docket Text: ORAL ORDER: The Rule 16(b) Conference set for 12/10/2020, is CANCELED. Ordered by Judge Richard G. Andrews on 12/8/2020. Associated Cases: 1:20-cv-00985-RGA, 1:20-cv-00986-RGA, 1:20-cv-01021-RGA, 1:20-cv-01022-RGA, 1:20-cv-01029-RGA(nms) |
| Nov 24, 2020 | 15 | Order Setting Scheduling Conference (1) Docket Text: Order Setting Rule 16(b) Telephone Conference: A Scheduling Conference is set for 12/10/2020, at 9:00 AM before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 11/24/2020. (nms) |
| Sep 22, 2020 | 14 | Answer to Counterclaim (5) Docket Text: ANSWER to [10] Answer to Complaint and Counterclaim, by ACADIA Pharmaceuticals Inc..(Taylor, James) Modified on 9/23/2020 (nms). |
| Sep 15, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [13] MOTION for Pro Hac Vice Appearance of Attorney George J. Barry III and Attorney Timothy H. Kratz, filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited. Signed by Judge Richard G. Andrews on 9/15/2020. (nms) |
| Sep 15, 2020 | 13 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney George J. Barry III and Attorney Timothy H. Kratz - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Sep 1, 2020 | 10 | Main Document (19) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against ACADIA Pharmaceuticals Inc. by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F)(Dorsney, Kenneth) |
| Sep 1, 2020 | 10 | Exhibit A (29) |
| Sep 1, 2020 | 10 | Exhibit B (35) |
| Sep 1, 2020 | 10 | Exhibit C (28) |
| Sep 1, 2020 | 10 | Exhibit D (29) |
| Sep 1, 2020 | 10 | Exhibit E (27) |
| Sep 1, 2020 | 10 | Exhibit F (27) |
| Sep 1, 2020 | 11 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma, Ltd. for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Sep 1, 2020 | 12 | Patent/Trademark Report to Commissioner (2) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,659,285 ;7,923,564 ;8,618,130 ;8,921,393 ;9,566,271 ;10,028,944 . (Dorsney, Kenneth) |
| Aug 17, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [9] STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to September 1, 2020 (*Reset Answer Deadlines: Aurobindo Pharma Limited answer due 9/1/2020; Aurobindo Pharma USA, Inc. answer due 9/1/2020). Signed by Judge Richard G. Andrews on 8/17/2020. (nms) |
| Aug 10, 2020 | 9 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendants Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. to answer, move or otherwise respond to the Complaint to September 1, 2020 - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Aug 4, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Chad J. Peterman, Bruce M. Wexler, Scott F. Peachman for ACADIA Pharmaceuticals Inc. and ACADIA Pharmaceuticals Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:20-cv-00986-RGA, 1:20-cv-00985-RGA(kmd) |
| Aug 4, 2020 | 8 | Main Document (2) Docket Text: AFFIDAVIT of Service for Complaint served on Timothy H. Kratz, Esq. on July 28, 2020, filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit A & B)(Taylor, James) |
| Aug 4, 2020 | 8 | Exhibit A & B (7) |
| Aug 3, 2020 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Added Related Cases per Letter Dated 7/31/20. Associated Cases: 1:20-cv-00986-RGA, 1:20-cv-00985-RGA, 1:20-cv-01021-UNA, 1:20-cv-01022-UNA, 1:20-cv-01029-UNA(rwc) |
| Jul 29, 2020 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:20-cv-00985-RGA, 1:20-cv-00986-RGA (rjb) |
| Jul 29, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [7] MOTION for Pro Hac Vice Appearance of Attorney Chad J. Peterman, Bruce M. Wexler, Scott F. Peachman, filed by ACADIA Pharmaceuticals Inc.. Signed by Judge Richard G. Andrews on 7/29/2020. (nms) |
| Jul 29, 2020 | 7 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Chad J. Peterman, Bruce M. Wexler, Scott F. Peachman - filed by ACADIA Pharmaceuticals Inc.. (Taylor, James) |
| Jul 28, 2020 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by ACADIA Pharmaceuticals Inc.. Aurobindo Pharma USA, Inc. served on 7/28/2020, answer due 8/18/2020. (Taylor, James) |
| Jul 27, 2020 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (mal) |
| Jul 27, 2020 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by ACADIA Pharmaceuticals Inc.. (Taylor, James) |
| Jul 24, 2020 | 1 | Main Document (13) Docket Text: COMPLAINT filed against Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number ADEDC-3084868.) - filed by ACADIA Pharmaceuticals Inc.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Civil Cover Sheet)(mal) |
| Jul 24, 2020 | 1 | Exhibit A (32) |
| Jul 24, 2020 | 1 | Exhibit B (37) |
| Jul 24, 2020 | 1 | Exhibit C (22) |
| Jul 24, 2020 | 1 | Exhibit D (23) |
| Jul 24, 2020 | 1 | Civil Cover Sheet (2) |
| Jul 24, 2020 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Jul 24, 2020 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 18, 2020. Date of Expiration of Patent: see attached. Thirty Month Stay Deadline: see attached. (mal) |
| Jul 24, 2020 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,646,480. (mal) |
| Jul 24, 2020 | 1 | Complaint* (1) |
